Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States.

Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada.

"The launch of HULIO, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the United States. This launch builds on our strong presence in oncology and diabetes and re-affirms our commitment to enabling affordable access to biologics," says Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, in a news release.

"Biocon Biologics is pleased to make HULIO®, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases. There are no buttons to push. Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don't have to miss a beat with HULIO®; they simply, 'Click, Click, Go,'" adds Mathew Erick, Chief Commercial Officer of Advanced Markets, Biocon Biologics Ltd.  

To provide broad access for patients, Biocon Biologics is offering two options to health plans and pharmacy benefit managers. HULIO is available at a list price (Wholesale Acquisition Cost) of 5% below the current Humira list price. Adalimumab-fkjp is also available at a list price of approximately 85% below the current Humira list price.